Wednesday, November 18

MHRA Unveils Innovative Programme to Address Evidence Gaps in Women’s Health

Women are set to benefit from improved evidence regarding medicines and medical devices, including insights into how their risks and benefits may differ from those experienced by men. This initiative, launched today by the Medicines and Healthcare products Regulatory Agency (MHRA), seeks to address longstanding disparities in healthcare research and treatment.

Despite constituting 51% of the population, women have historically been underrepresented in clinical research, which has resulted in significant gaps in available evidence pertaining to medicines and medical devices, particularly in relation to pregnancy and reproductive health. There remain unmet medical needs for conditions that are specific to women or that manifest differently in female patients.

Addressing Representation Gaps in Clinical Trials

An analysis conducted by the MHRA of all 4,616 clinical trial applications submitted in the UK between 2019 and 2023 has revealed continued underrepresentation of women in clinical studies. Alarmingly, only 1.1% of trials included pregnant women, while a mere 0.6% involved breastfeeding participants.

The newly launched Women’s Health Programme aims to tackle these challenges head-on by exploring how enhanced data collection and scientific advancements can more accurately reflect the unique health needs of women.

Baroness Gillian Merron, the Women’s Health Minister, expressed her support for the programme, stating, “For too long, women’s health has been overlooked. Women make up more than half of our population, yet they have been underrepresented in the research that shapes the medicines and devices they rely on. That is not good enough, and we are determined to change it.” She added that this initiative, alongside the renewed Women’s Health Strategy, promises improved evidence and treatments tailored to women’s needs.

READ:  Government Supports Local Journalism with £6 Million Funding as Careers Campaign Engages Thousands of Young People

Opportunities for Better Healthcare Solutions

Lawrence Tallon, Chief Executive of the MHRA, highlighted the potential benefits of bridging these knowledge gaps: “Closing the gaps in our understanding of how the risks and benefits of medicines and medical devices differ for women is both a challenge and a huge opportunity. Better evidence can help us understand where important differences exist and support researchers and innovators in developing healthcare solutions that cater specifically to women’s needs.”

With the complexity of medicines and medical devices, various factors such as biology, age, and health conditions can influence individual responses. The programme is designed to unite patients, researchers, healthcare professionals, and industry representatives to enhance the evidence base while adhering to high safety and effectiveness standards.

Innovation in Women’s Health and Emerging Technologies

Women’s health represents a significant area for innovation, with the UK’s burgeoning FemTech sector currently generating an annual turnover of nearly £300 million. Innovations are being developed across various domains, from reproductive health to chronic conditions and healthy ageing.

By collaborating with researchers and innovators from the outset and establishing a solid evidence base regarding how the risks and benefits of medicines may differ for women, the MHRA aims to nurture an ecosystem where promising new products can be swiftly developed and made accessible to patients.

Naho Yamazaki, Deputy Director of Policy and Partnerships at the Health Research Authority, commended the initiative, stating, “We welcome the MHRA’s Women’s Health Programme and its ambition to strengthen the evidence base for women’s health. It is essential that under-represented groups are included in clinical trials, ensuring that research yields evidence relevant to the populations who will ultimately benefit from new treatments.”

READ:  Prime Minister's Keynote Address at the National Economic Council: 30th October 2026

Collaborative Efforts Toward Inclusivity

Yamazaki further emphasised the importance of the joint guidance with the MHRA on developing an Inclusion and Diversity Plan, which provides a practical framework for researchers to consider inclusivity from the early stages of study design. This initiative aims to prevent the exclusion of women, girls, and those who are pregnant or breastfeeding from research pertinent to their health.

Michelle Riddalls OBE, CEO of PAGB, The Consumer Healthcare Association, expressed optimism regarding the MHRA’s focus on bridging evidence gaps and promoting responsible innovation. “Better evidence can empower women to make informed healthcare choices and expand access to appropriate treatments,” she noted, citing recent successful reclassifications of certain Hormone Replacement Therapy (HRT) products as positive strides towards enhancing women’s health options.

Future Directions and Health Equity

The Women’s Health Programme has been developed with input from patients, including contributions from the MHRA’s Patient and Public Community and focus groups facilitated by the Patients Association. This initiative marks the initial phase of a broader MHRA strategy aimed at addressing health inequalities, as outlined in the recently unveiled 2030 Strategy.

As part of the UK government’s renewed commitment to improve women’s health through the Women’s Health Strategy for England, the programme represents a regulatory effort to ensure that women’s health considerations are integral to healthcare innovation.

The announcement of this programme coincides with the inaugural DIA-MHRA Global Summit, taking place in London on 16-17 November 2026, during London Life Sciences Week. This summit will gather international regulators, industry experts, researchers, healthcare professionals, and patient advocates to discuss how global collaboration can accelerate innovation and enhance patient access to new treatments.

READ:  Diversity Summer Scheme 2026: Cultivating Future Leaders in Government Law

Leave a Reply

Your email address will not be published. Required fields are marked *